drugset

drugset / Trial / NCT01973309

A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

NCT01973309 ↗

Phase 1 Completed 37 enrolled OncoMed Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with paclitaxel.

Timeline

Start: 2013-09
Primary completion: 2017-06
Completion: 2017-12

Publications

Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun AM, Xu L, Stagg B, Uttamsingh S, Brachmann RK, Farooki A, Mita M. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53-62. doi: 10.1007/s10549-020-05817-w. Epub 2020 Aug 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vantictumab	Monoclonal antibody	—	Intravenous
Background	Paclitaxel	Small molecule	90 mg/m2	Intravenous

Indications